Member Info for spbhoy

Collinson is not in competition to AVCT/ODX/GDR etc. They are a provider of services ......from their website "Create better experiences for your travelling customers with our proprietary travel benefit programmes, including world leader Priority Pass."
They must therefore be buying any products they are using or trialling from another supplier.

BBC now quoting £140 per test....Wow, now that's inflation for you. It was only £120 per person according to the Times earlier this morning. LOL.

If it's us then I'm sure we'll get an RNS to clarify and also to clarify the price. If t is another test then I'd expect/hope that Cytiva/Avacta would RNS something ASAP to counter ant detrimental reaction...even just for PR purposes. The best is always worth waiting for.

It was several weeks ago, but I seem to recall AS mentioning $30 per test as being an expected cost.

spread at almost 5p at one point .lol

I’ve seen it posted elsewhere that I’d you place a fill or kill order at or within the market size (5k shares for AVCT) then the MMS are obliged to complete the trade or must move the prices...perhaps someone else could confirm

Remember the "report" button. It is the best solution for ridding the board of deliberately disruptive posts.

Failing that, remember the "filter" button as that is the second defence against deliberately disruptive nonsense.

@mapp. Seriously?? Within half an hour of ****ging TW you sell part of your holding. Find a mirror and take a good look.

It'll probably break £1.40 twice before it does so a third time as they might still need to flush out a few weak holders at the £1.40 bid first.....a few will have missed it earlier on. Then we'll hopefully shift on upwards.

@Investor2210, You ought to be okay. Lots of traders would have jumped out at £1.30-£1.40 to take their 10%...but savvy buyers will wait out the first hour before making their move to buy. Hopefully we should rise again very soon.

@Canute40...Agreed. David from Avacta was uber positive in his statement and when you consider how many negatives he spoke about at the start (in his first contribution), it definitely sounds like they have managed to do the high specificity that an antigen test requires. Good on him.

He even went on to try and explain why they had been talking about challenges....almost as if there was some pride in explaining how many challenges they have faced....just the sort of thing someone with a completed or near completed product might want to do.

Thank God for Klaus that this is a remote discussion as the others would surely give him a good kicking if it was in one location. He's certainly not a glass half full type of guy. Well done David Wilson

Klaus..."getting a high enough specificity is doable"....David (Avacta)..."it's more than doable....WE CAN DO IT"

Has anyone else still got a live feed on the Q&A

Yes Timster. Unfortunately this virus has a long way to run

Just submitted my question "lost of obstacles have been discussed, but could any of the panel confirm if many of these obstacles still remain or have been overcome?"

Let's remember, as already mentioned by seethreeIPO and PL75, this is not a sales pitch type of webinar. It's a bunch of scientists discussing the subject and the problems that they have and/or are encountering.

Klaus from Cytiva seems to be suggesting/hinting that we need a combined antigen/antibody test...if i understood him correctly. Might be something that they are aiming for and obviously there Affimer tech would help with that.

David Wilson from Avacta needs to stop focusing on the negatives. Not a good speaker

"We will need to test for a very long time" quote from Klaus Hochleitner (Cytiva)

@hants...I signed up a few days ago and had to register with Labroots, but got it done in a few minutes:

YOU'RE ALL SET
Hi P*****
Thank you for registering for the Coronavirus Virtual Webinar Series.
The first event was a great success! It is now available for on-demand viewing.
Our next event of the webinar series will go live on June 17th. Set a reminder
The webinar series will be ongoing through the end of 2020. The webinars will be available for unlimited on-demand viewing.
Be sure to share this event with a colleague and use #LRcoronavirus to follow the conversation!